Gold Biotechnology, Inc.’s Post

RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste. In a new paper published today in Nature Biotechnology, a team of researchers from the Wyss Institute and Harvard Medical School report a new, enzyme-based RNA synthesis method that can produce strands of RNA with both natural and modified nucleotides without the environmental hazards. This approach enables the rapid scale-up needed to meet the growing demand for RNA therapeutics, and is being commercialized by Wyss startup EnPlusOne Biosciences. Northpond Ventures Jonathan Rittichier Daniel Wiegand Erkin Kuru #Oligonucleotides #RNA #Therapeutics #StartupNews https://lnkd.in/eqc3rXqp

Biomarkers Market Size To Hit USD 93.8 Billion by 2029 Download Free Sample Report-https://lnkd.in/dmKwWDPH The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies Working in the Market NANOVERY CBmed GmbH Proteome Sciences plc HistologiX Cavidi Dawako Medtech BIOMED-UHasselt OmicScouts Dxcover A4P, A LabConnect Company Resolve Stroke Wellabe Alivion ABCDx SA   RumeXperts ProAxsis Cleara Biotech B.V. York Bioanalytical Solutions   AIT Bioscience ET Healthcare Envol Biomedical LinusBio ARBOR ASSAYS Interleukin Genetics MedQIA, LLC Decode Health Pangea Laboratory BioFluidica, Inc. WaferGen Biosystems Ethos Biosciences Neurosteer Vigilant Biosciences, Inc.  Hyperion Biotechnology, Inc. MiraDX, Inc.

Biomarkers Market Size To Hit USD 93.8 Billion by 2029 Download Free Sample Report-https://lnkd.in/dmKwWDPH The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies Working in the Market NANOVERY CBmed GmbH Proteome Sciences plc HistologiX Cavidi Dawako Medtech BIOMED-UHasselt OmicScouts Dxcover A4P, A LabConnect Company Resolve Stroke Wellabe Alivion ABCDx SA   RumeXperts ProAxsis Cleara Biotech B.V. York Bioanalytical Solutions   AIT Bioscience ET Healthcare Envol Biomedical LinusBio ARBOR ASSAYS Interleukin Genetics MedQIA, LLC Decode Health Pangea Laboratory BioFluidica, Inc. WaferGen Biosystems Ethos Biosciences Neurosteer Vigilant Biosciences, Inc.  Hyperion Biotechnology, Inc. MiraDX, Inc.

The future of cancer treatment could be brewing in a lab, thanks to the genetic manipulation of yeast? 🧬✨ Cell factory technology is revolutionizing biotechnology, allowing us to engineer yeast cells to produce targeted compounds like anti-cancer drugs. This innovative approach not only streamlines the process of drug production but also holds the promise of making treatments more accessible and cost-effective. Benefits of Cell Factory Technology: Targeted Treatment: Precision engineering of yeast cells ensures the production of specific compounds essential for cancer treatment. Enhanced Efficiency: Faster and more efficient drug production processes mean quicker access to life-saving medications. Cost-Effectiveness: Reducing the cost of drug development and production can make treatments more affordable for patients worldwide. The impact of biotechnology on world health is undeniable, and as we continue to explore the potential of cell factory technology, the future looks brighter than ever. Join us in celebrating this breakthrough and stay tuned for more innovations in the world of biotech! 🌟 #Biotechnology #CellFactory #CancerResearch #Innovation #ILB #FutureOfMedicine

Nano-Biotechnology: Tiny Innovations with Big Impact on Biologics In the rapidly evolving world of biotechnology, nano-sized innovations are making a monumental impact on biologics. Our latest blog post delves into how nanotechnology is transforming the landscape of biologics, offering groundbreaking advancements in drug delivery, diagnostic tools, and therapeutic solutions. Dive into the fascinating intersection of nanotechnology and biologics and understand how these tiny innovations are driving substantial progress in the field. Read the full blog here: https://lnkd.in/e_Gdu27X For more insights on the latest biotechnological advancements and how they can benefit your projects, contact us at [email protected]. Let’s shape the future of biotechnology together! #NanoBiotechnology #Biologics #Innovation #DrugDelivery #Diagnostics #PharmaTech #HealthTech #Biotech #FutureOfMedicine #ResearchAndDevelopment

Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation https://lnkd.in/gwVD-TNM A-Alpha Bio, a Seattle-based biotechnology company, announced the Department of Defense has awarded the company another $14.5M to accelerate its antibody discovery and optimize for biothreats. According to A-Alpha Bio cofounder and CEO, David Younger, PHD, “We’ve measured 10 million interactions in this collaboration and have focused so far on three pathogenic families. This extension of funding will allow us to really broaden both our potential impact on pandemic preparedness and our interest in training more generalizable models. Having an interaction space that covers more pathogen diversity is exactly what we’re interested in doing.” The post Bud-wiser: DOD Backs A-Alpha Bio for Biothreat Preparation appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

To help frame the discussion at #BioCenturyGrandRounds, Insights Partner McKinsey & Company will unveil an exclusive conference report examining the current state of biopharma research and where translation is headed. Biotechnology breakthroughs rely on efficient and effective mechanisms to advance high-potential translational research. At a moment of accelerated biopharma innovation, there is an opportunity for industry, academia and other stakeholders to collaborate in new ways to help unlock the next wave of breakthrough therapies. The panel will be moderated by McKinsey & Company Partners Peter Wright and Guang Yang, Ph.D.. Download the conference brochure to view the full agenda: https://lnkd.in/gtP_xdri Register and learn more at https://lnkd.in/gmhZ75vm. #biopharma #translation #biotechnology

Exciting advancements in biotechnology! Plant-derived Exosomes (PDENs) are not only essential for cell communication but also have healing and rejuvenating properties. By transporting proteins and mRNA between cells, PDENs play a crucial role in repairing mitochondria promoting overall health and healing. #biotech #cellcommunication #healingproperties #exosomes

Another chapter in our collaboration with @biocentury to create platforms for exchanges among industry executives across the ecosystem.

A series of new studies, published within the past year, leverage groundbreaking research from 2022 and 2023 by the Institute for Protein Design, University of Washington and the Baker Lab. This prior work included designing 👉 custom enzymes, 🤞 proteins capable of crossing cell membranes, and demonstrating 🤘 how reinforcement learning, a technique used in games like chess, can be applied to design new molecules. ❤️ RFantibody (March 18, preprint): This new tool designs antibodies, powerful molecules that target specific therapeutic areas. (Note: This is a preprint and has not yet been peer-reviewed) ❤️ Biomaterial toolkit (March 13, Nature): This toolkit simplifies the construction of biomaterials, potentially leading to new applications. 💓 Protein hydrogels (Jan. 30, PNAS): Researchers developed hydrogels that assemble proteins within 3D scaffolds, both inside and outside cells. 💙 Protein-biomarker binding (Dec. 18, Nature): RFdiffusion, combined with another IPD tool (ProteinMPNN), designed proteins that efficiently bind to biomarkers like human hormones. 💚 Carbon-storing minerals (Dec. 14, Nature Communications): Engineered organisms were used to create carbon-rich minerals, potentially forming the basis for carbon storage. 💛 Protein crystals (Oct. 16, Nature Materials): Designing protein crystals paves the way for new optical tools, separation technologies, and more. 💜 Protein fibers (Sept. 4, Nature Chemistry): These silk-like protein fibers open doors for novel textiles and bioengineering applications. 🖤 Switch-like proteins (Aug. 17, Science): Proteins that change between two shapes could be used as environmental sensors or smart therapeutics. 💝 RFdiffusion (July 11, Nature): This innovative method starts with "pure static" and refines it into a protein structure. WuXi Biologics WuXi Biologics CRO Services is a leading provider and we produce various antibodies and Proteins based on your needs. Check out our past webinars: https://lnkd.in/gvYp52rM